Giant Cell Arteritis and Polymyalgia Rheumatica

• Adaptive immune activation and T-cell dysfunction: The primary mechanism involves activation of CD4+ and CD8+ T cells specific to antigens within the arterial wall, likely triggered by molecular mimicry following infections (parvovirus B19, Chlamydia pneumoniae, or other respiratory pathogens remain suspected but unproven triggers). Interleukin-6 (IL-6) and interleukin-17 (IL-17) production by activated T cells drives the inflammatory cascade. Autoreactive T cells infiltrate the temporal artery adventitia and media, particularly at the internal elastic lamina where they encounter dendritic cells and resident macrophages. The loss of regulatory T-cell (Treg) function, demonstrable in elderly GCA patients, permits unopposed effector T-cell expansion. This T-cell activation paradoxically occurs despite overall T-cell lymphopenia and immune dysregulation characteristic of aging ("inflammaging").

• Macrophage-mediated vascular injury and intimal proliferation: Activated macrophages in the arterial wall undergo M1-type polarization with high production of tumor necrosis factor-alpha (TNF-α), IL-1β, and IL-6, perpetuating local inflammation. Macrophages release vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF), which stimulate smooth muscle cell proliferation and migration from the media to the intima, causing concentric intimal hyperplasia. This arterial remodeling narrows the arterial lumen and reduces blood flow, explaining the ischemic complications. CD163+ macrophages within granulomas produce soluble transferrin receptor, contributing to iron sequestration and the anemia of chronic inflammation. The chronic phase of GCA is characterized by fibrosis of the vessel wall with progressive intimal thickening and luminal obliteration, even after effective corticosteroid suppression of acute inflammation.

• B-cell activation, autoantibodies, and immune complex formation: B cells are also activated in GCA, producing antibodies against several putative autoantigens, including oxidized lipoproteins and heat shock proteins. Immune complexes may deposit in vessel walls, though the primary pathology remains T-cell and macrophage-mediated rather than immune complex-driven. High circulating levels of IL-6, derived from inflamed tissues and activated immune cells, drive acute-phase reactant production by hepatocytes, explaining the markedly elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) that characterize both GCA and PMR.

• Genetic predisposition and HLA association: Twin and family studies confirm familial clustering and heritable susceptibility. Multiple genome-wide association studies have identified associations with HLA-DR4 and HLA-DRB1 alleles, which likely influence T-cell recognition of relevant arterial autoantigens. Non-HLA genetic factors, including polymorphisms in PTPN22 (protein tyrosine phosphatase), IL-6 signaling genes, and TNFAIP3, also contribute to disease risk. These genetic factors alone are insufficient for disease—environmental triggers (infections, vaccinations) are likely required in genetically predisposed individuals.

• Age-related immune changes and vascular vulnerability: The aging immune system shows impaired T-cell selection in the thymus, reduced Treg function, altered dendritic cell maturation, and increased production of pro-inflammatory cytokines—collectively termed "inflammaging." Simultaneously, the aging arterial wall undergoes structural changes with increased elastin fragmentation, collagen deposition, and reduced compliance, potentially increasing susceptibility to immune attack. Oxidative stress and endothelial dysfunction increase with age, creating an environment permissive for autoimmune activation.

• Pathophysiology of polymyalgia rheumatica: The mechanism of PMR-related muscle pain remains incompletely understood but likely involves intramuscular or perivascular inflammation rather than primary muscle fiber pathology, as muscle biopsies show minimal myositis. Elevated IL-6, TNF-α, and other inflammatory mediators within affected muscles and their microvascular beds may stimulate nociceptors and cause the characteristic pain and morning stiffness. Some evidence suggests involvement of the glenohumeral and hip synovial membranes with inflammatory infiltration. The morning stiffness reflects the accumulation of inflammatory cytokines and metabolites during periods of immobility, which dissipate with activity and systemic corticosteroid suppression of IL-6 production.

• Advanced age (>50 years): Age is the single most important risk factor, with incidence increasing logarithmically with advancing age; the median age at diagnosis is approximately 70–75 years. This reflects the cumulative effects of aging-related immune dysregulation and vascular changes. The rarity of disease onset before age 50 is so reliable that diagnosis in younger patients warrants investigation for alternative diagnoses.

• Northern European ancestry and genetic predisposition: Scandinavian and Northern European populations show 5–10-fold higher incidence compared with African, Hispanic, and Asian populations, reflecting both genetic susceptibility (HLA associations) and possibly environmental factors (infectious triggers prevalent in these regions). White race is the predominant demographic affected, with disease extremely rare in African Americans and other non-European ancestry groups.

• Female predominance: Women account for 60–70% of GCA and PMR cases, a 2:1 female-to-male ratio. The mechanism is unclear but likely involves the interaction of female sex hormones (estrogen-mediated immune activation) with aging-related immune changes and vascular alterations.

• Preceding or concurrent infections: While no single pathogen has been definitively identified, serologic studies and molecular evidence have implicated parvovirus B19, Chlamydia pneumoniae, cytomegalovirus, and other respiratory viruses as potential triggers. Molecular mimicry—where pathogen-derived antigens structurally resemble self-antigens in the arterial wall—is a proposed mechanism.

• Vaccinations (temporal association): Retrospective case-control studies have shown temporal clustering of disease onset within weeks to months following influenza and pneumococcal vaccinations in some patients, though causality remains unproven and the risk is vastly outweighed by vaccination benefits. This association likely represents coincidental timing in a susceptible population approaching disease threshold rather than true causation.

• Other autoimmune and inflammatory conditions: Patients with prior autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, Sjögren syndrome) may have modestly increased risk, though GCA and PMR typically occur in isolation without concurrent autoimmune disease.

Polymyalgia Rheumatica—Cardinal Features

• Proximal muscle pain and stiffness: The hallmark symptom, affecting shoulders (90%), hips and pelvis (70%), and neck (50%). Pain is typically bilateral and symmetrical, worse in the morning (lasting >30 minutes and often 2–3 hours), and improves with activity and movement. Patients report difficulty with overhead activities (combing hair, reaching into cabinets), rising from chairs, and climbing stairs. The stiffness results from inflammatory cytokine-induced muscle pain and microvascular inflammation rather than primary myopathy; manual muscle testing is normal, and creatine kinase (CK) is normal or only mildly elevated. The symptoms dramatically improve within 24–48 hours of initiating corticosteroids, which is both diagnostically and therapeutically important.

• Systemic inflammatory symptoms: Fever (usually low-grade, 37.5–38.5°C), malaise, fatigue, and weight loss (2–10 kg) occur in 50% of patients. These reflect high circulating levels of IL-6 and TNF-α.

• Anemia of chronic inflammation: A normocytic, normochromic anemia is present in up to 50% of PMR patients at diagnosis, with hemoglobin typically 8–11 g/dL, resulting from IL-6-mediated hepcidin production and iron sequestration.

• Arthralgias and arthritis: Some patients develop inflammatory polyarthritis, particularly affecting knees, wrists, and small joints of the hands, mimicking rheumatoid arthritis in presentation. Synovitis on ultrasound or MRI of shoulders and hips confirms the inflammatory nature of PMR.

Giant Cell Arteritis—Clinical Manifestations

• Temporal headache: Present in 50–80% of GCA patients, classically described as new-onset, localized headache over the temporal region, scalp, or occiput. The pain is often described as throbbing or constant and frequently severe enough to require analgesics. Temporal artery inflammation causes the pain through stretching of the periosteum and nociceptor stimulation. The "scalp tenderness" sign—pain with gentle palpation or combing of hair—is highly suggestive and reflects superficial temporal artery inflammation. Headache that awakens patients from sleep is particularly concerning for GCA.

• Vision symptoms and visual loss (ophthalmologic emergency): Approximately 40–50% of untreated GCA patients develop vision complications, representing the most catastrophic consequence of the disease. Amaurosis fugax (transient vision loss, described as a "curtain" descending over vision) reflects transient ischemia of the ophthalmic artery territory and is an urgent warning sign. Anterior ischemic optic neuropathy (AION) results from ischemia of the optic nerve head when the posterior ciliary arteries are involved; patients report sudden, painless, often profound vision loss (monocular) with an afferent pupillary defect and a relative scotoma on visual field testing. The optic disc appears pale and swollen acutely. AION is irreversible and often progresses to fellow eye in untreated patients within days to weeks. Central retinal artery occlusion (CRAO), though less common, causes sudden, painless monocular blindness with a pale "cherry-red spot" on fundoscopy. These ischemic events reflect luminal narrowing and occlusion of orbital vessels by intimal proliferation and local thrombosis.

• Jaw claudication: A distinctive symptom reported in 5–10% of GCA patients, representing claudication of the masseter muscles during chewing. Patients report jaw pain while eating solid foods or even during prolonged talking, thought to reflect external carotid artery involvement. When present, jaw claudication is highly specific for GCA and associated with increased risk of vision loss.

• Limb claudication and large-vessel disease: Occurs in 10–15% of GCA patients, typically affecting the upper extremities more than lower extremities. Patients report arm pain with activity (subclavian and axillary artery involvement). On examination, asymmetric blood pressure measurements between arms (>20 mmHg difference) or diminished pulses suggest aortic arch and branch vessel involvement. This large-vessel vasculitis component may be clinically occult, detectable only on imaging studies.

• Fever and systemic symptoms: Low-grade fever, malaise, and constitutional symptoms are common in GCA, often preceding or accompanying vascular symptoms.

• Aortic complications: In advanced cases, aortic arch syndrome with proximal aortic involvement can lead to aortic regurgitation (new diastolic murmur, wide pulse pressure), aortic dissection, or aortic rupture, though these represent late and uncommon presentations.

Physical Examination Findings

• Temporal artery examination: Palpate both temporal arteries along their course anterior to the ear. In GCA, the artery may be visibly prominent, tender, nodular, or even non-pulsatile (indicating severe stenosis/occlusion). However, a normal-appearing temporal artery does not exclude GCA—absence of findings does not reduce probability significantly. Some patients have thickened, prominent temporal arteries without tenderness.

• Scalp tenderness: Gentle percussion or palpation over the scalp may elicit pain, reflecting inflammation of superficial temporal artery branches.

• Asymmetric pulses or blood pressures: Perform bilateral blood pressure measurements and assess carotid, brachial, radial, femoral, and pedal pulses. Diminished or absent pulses in the upper extremities suggest aortic branch involvement.

• New cardiac murmurs: A new diastolic murmur at the left upper sternal border indicates aortic regurgitation from aortic root involvement.

• Proximal muscle strength: Normal strength despite patient-reported muscle pain distinguishes PMR from myopathy or myositis.

Important Clinical Variants and Presentations

• Isolated large-vessel vasculitis: Approximately 10–15% of GCA patients present with predominantly large-vessel disease (aorta and proximal branches) without cranial symptoms, referred to as "aortitis" or Takayasu-like GCA. These patients may present with arm claudication, aortic regurgitation, or constitutional symptoms without headache or vision signs, making diagnosis more challenging.

• GCA without prominent headache: Approximately 20% of GCA patients never develop headache, instead presenting with constitutional symptoms and systemic manifestations. This variant is easily missed if cranial symptoms are expected.

• PMR-only presentation: Approximately 80–85% of patients with PMR do not develop GCA during their illness, though careful evaluation for vascular involvement (imaging, temporal artery biopsy in selected cases) is warranted.

• Relapsing-remitting disease: Some patients experience multiple relapses of PMR/GCA symptoms during tapering of corticosteroids or even at stable doses, requiring dose adjustment or additional immunosuppressive therapy.

Clinical Diagnostic Criteria

Laboratory Investigations

• Erythrocyte sedimentation rate (ESR): Markedly elevated in >90% of both GCA and PMR cases, typically 50–100+ mm/h (Westergren). Normal ESR does not exclude GCA—approximately 5–10% of biopsy-proven GCA patients have ESR <50 mm/h, particularly elderly patients. ESR elevation reflects high IL-6 levels driving hepatic fibrinogen and immunoglobulin production

Immediate stabilisation — treat on suspicion, not on biopsy

• Glucocorticoids before confirmation: The 2021 ACR/Vasculitis Foundation GCA guideline states that high-dose glucocorticoids should be started immediately when GCA is strongly suspected; temporal artery histology remains interpretable for roughly two weeks after steroids begin, so nothing diagnostic is lost. Delay risks irreversible optic nerve infarction.
• Any visual symptom (amaurosis fugax, AION, CRAO) is an emergency: pulse IV methylprednisolone 1000 mg daily for 3 days, then oral prednisone. Restoring perfusion to an already infarcted nerve head is not expected; the goal is protecting the fellow eye.
• Uncomplicated cranial GCA: oral prednisone 40–60 mg daily as a single morning dose.
• PMR without GCA features: much lower dosing — prednisone 12.5–25 mg daily per the 2015 ACR/EULAR PMR recommendations. Failure to improve dramatically within days argues against PMR.

Steroid-sparing escalation

• IL-6 receptor antagonist (tocilizumab): ACR/VF 2021 favors glucocorticoids plus tocilizumab over glucocorticoids alone in newly diagnosed GCA, based on the GiACTA trial showing higher sustained remission and lower cumulative steroid exposure. Mechanistically it blocks the IL-6 axis driving both the vasculitis and the acute-phase response.
• Antimetabolite (methotrexate): alternative adjunct when tocilizumab is unavailable or contraindicated, and considered in relapsing or high-risk PMR under ACR/EULAR guidance. Give folic acid.
• Taper: slow, relapse-guided taper over many months; relapse is managed by re-escalation plus adding a steroid-sparing agent.

Prophylaxis against therapy toxicity

• Bone protection: calcium, vitamin D, and a bisphosphonate per the ACR glucocorticoid-induced osteoporosis guideline; also monitor glucose, blood pressure, and for cataract/glaucoma.

What not to do

• NSAID monotherapy does not prevent blindness and is not treatment for GCA.
• TNF inhibitors have not shown benefit in GCA and are not recommended.
• Routine aspirin is not endorsed for GCA absent another indication.
• Abrupt steroid withdrawal risks adrenal crisis; taper always.
• Temporal artery biopsy is diagnostic, not therapeutic; the only surgery relevant is repair of a thoracic aortic aneurysm meeting ACC/AHA aortic disease size/growth criteria.

Disease-related — ischemic (emergencies)

• Anterior ischemic optic neuropathy: occlusion of the posterior ciliary arteries by intimal hyperplasia and thrombosis infarcts the optic nerve head. Signaled by sudden painless monocular vision loss with an afferent pupillary defect and a pale, swollen disc. Irreversible; the untreated fellow eye is at high short-term risk.
• Central retinal artery occlusion: painless monocular blindness with a cherry-red spot. Same urgency and same treatment.
• Stroke, especially vertebrobasilar: GCA has a predilection for the vertebral arteries, so posterior circulation infarction (diplopia, ataxia, cortical blindness) is the classic vasculitic stroke pattern.
• Scalp or tongue necrosis: rare, indicates severe external carotid branch occlusion and very active disease.

Disease-related — late large-vessel

• Thoracic aortic aneurysm and dissection: chronic medial inflammation with elastin destruction weakens the aortic wall years after apparent remission. Signaled by a new diastolic murmur of aortic regurgitation, widened mediastinum, or tearing chest/back pain (dissection is an emergency). Periodic aortic imaging surveillance is advised in GCA survivors.
• Subclavian/axillary stenosis: arm claudication, absent pulses, and an interarm systolic blood pressure difference.

Treatment-related

• Glucocorticoid toxicity dominates long-term morbidity: vertebral compression fracture (assess bone density; ACR glucocorticoid-induced osteoporosis guidance), new or worsened hyperglycemia, hypertension, weight gain and Cushingoid habitus, cataract and glaucoma, proximal steroid myopathy (a mimic of PMR relapse but with true weakness and normal inflammatory markers), psychiatric effects, and opportunistic infection. Abrupt withdrawal after prolonged therapy precipitates adrenal crisis — hypotension, hyponatremia, hypoglycemia — an emergency.
• Tocilizumab: gastrointestinal perforation, particularly with diverticular disease — new abdominal pain with peritoneal signs is an emergency; also neutropenia and transaminase elevation. Critically, IL-6 blockade normalizes ESR and CRP, so acute-phase reactants can no longer be used to detect a flare.
• Methotrexate: cytopenias, hepatotoxicity, mucositis, and pneumonitis.

• The single best next step in a suspected GCA stem is high-dose glucocorticoids, then biopsy — never the reverse. If the stem mentions any visual symptom, the answer is IV methylprednisolone; if vision is intact, oral prednisone. Ordering the biopsy first is the most common trap.
• Jaw claudication and diplopia carry the strongest predictive weight for a positive temporal artery biopsy — stronger than headache alone. Pain in the masseters while chewing in a patient over 50 is a near-giveaway.
• A normal ESR does not exclude GCA. Check CRP as well; a small minority of biopsy-proven cases have unimpressive sedimentation rates. "ESR was 30, so it isn't GCA" is a distractor.
• Biopsy technique is tested: take a long segment (generally ≥1 cm) because skip lesions make short specimens falsely negative; a negative unilateral biopsy in a high-probability patient does not overturn the diagnosis.
• PMR has pain and stiffness but no weakness and a normal CK. The distractor is polymyositis — that one has objective proximal weakness and a markedly elevated CK. Painless weakness ≠ PMR.
• Dose separates the two diseases: PMR responds to low-dose prednisone (12.5–25 mg), GCA needs 40–60 mg. Treating suspected GCA at PMR doses is a classic wrong answer.
• The association examiners like: HLA-DR4, and the long-term link to thoracic aortic aneurysm — a new aortic regurgitation murmur years after GCA is the disease, not a coincidence.
• Tocilizumab (anti-IL-6 receptor) is the guideline-endorsed steroid-sparing add-on per the 2021 ACR/Vasculitis Foundation guideline; remember it normalizes CRP/ESR, so inflammatory markers become useless for flare monitoring, and watch for GI perforation.
• Do not answer "aspirin" as routine GCA therapy, and do not answer a TNF inhibitor — neither is recommended.